Posted on

HAVN Life Announces Retail Partnership With Alberta Grocer, Calgary Co-op

HAVN Life Announces Retail Partnership With Alberta Grocer, Calgary Co-op

The Company’s full line of natural health formulations will be available at select locations starting in May

Vancouver, BC – Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce it has secured a product listing agreement with Calgary Co-op for the Company’s line of natural health products, launched in June of last year (the “Product Line”). The locally owned and operated grocery chain will carry the full line of HAVN Life natural health products in up to nineteen “Natural Choice” section locations throughout Alberta. The Product Line is expected to hit the shelves of select Calgary Co-op locations in May, 2022.

“We are excited to have our recently launched line of natural health products at select locations across Alberta,” says Tim Moore, CEO of HAVN Life. “As purveyors of natural, organic, and specialty foods, Calgary Co-op is aligned with our focus on health and wellness and we are thrilled to be expanding our distribution network to help build and empower healthy communities,” he adds.

Calgary Co-op is the third major specialty retail chain partner that HAVN Life has secured as part of the Company’s distribution strategy that includes retail, online and subscription channels to reach a broad customer base and deliver a quality product experience. Currently, the seven formulations are available at yourhavnlife.com, Well.ca, Amazon, and across select Choices & Nesters Market stores in British Columbia.

HAVN Life formulations are non-GMO, vegan, bioavailable, naturally-derived from functional mushrooms and other plants and created with human optimization in mind. The Product Line has been thoughtfully formulated with adaptogens and antioxidants to support overall brain health, with natural compounds that are proven to support memory, focus, energy, and overall cognitive function.

###
On Behalf of The Board of Directors
Tim Moore
Chief Executive Officer

About HAVN Life Sciences Inc.
HAVN Life Sciences is a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of APIs, the development of natural health products, and innovative therapies to support brain health and cognitive function.

Through its research division, HAVN Labs, the company has developed an end-to-end supply chain of GMP naturally derived psychedelic compounds for research that will define the future of modern medicine. With its new line of natural health products, HAVN Life offers a full range of high-quality mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle.

Purchase our products and find out more at yourhavnlife.com, and follow us on Facebook, Twitter, Instagram and Youtube.

About Calgary Co-op
Calgary Co-op is a member-owned group of stores with locations in Calgary, Airdrie, Cochrane, High River, Okotoks and Strathmore, and include food centres, pharmacies, gas stations, car washes, commercial cardlocks, home health care centres, wine, spirits and beer locations, as well as cannabis and Community Natural Foods, acquired in 2019. Serving Canadians since 1956, Calgary Co-op sources as much food as possible from Calgary, across Alberta, and throughout western Canada to provide fresh, farm-to-table, high-quality foods at the lowest possible prices.

With over 440,000 members, 3,850 employees, assets of $627 million and annual sales of $1.2 billion, Calgary Co-op has been recognized as one of Alberta’s Top 75 Employers for several years in a row and is committed to delivering an exceptional customer experience through inspired team members.

Contact:
Investor Relations: ir@havnlife.com 604 687-7130
Media: savi@emergence-creative.com 647 896-8078

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the product listing agreement in respect of the Company’s Product Line, the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that the listing of the Product Line at select Calgary Co-op locations pursuant to the product listing agreement will not be completed as contemplated, or at all, risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

Posted on

Doseology Launches Medicinal Mushroom Product Line in Canada to Supply Increasing Demand

Doseology Launches Medicinal Mushroom Product Line in Canada to Supply Increasing Demand

Vernon, British Columbia, February 23, 2022 – Doseology Sciences Inc. (CSE: MOOD) (“Doseology” or the “Company”), a British Columbia-based diversified life sciences company developing mushroom-based health and wellness solutions, announces the launch of its Health Canada NPN-approved medicinal mushroom product line in Canada, and preparation for a national multichannel marketing campaign.

About the Doseology Product Line
The Canadian product line includes five medicinal mushroom products for cognitive health benefits. Each product is formulated and positioned to compete in both the medicinal mushroom and nootropics markets, and each addresses different market needs, including mood, energy, recovery, sleep and focus.

Lion’s mane (Hericium erinaceus) is a popular nootropic (mind-enhancing) mushroom featured in three of the new products. A staple of eastern medicine and the subject of numerous recent studies, lion’s mane is thought to enhance creativity, sharpen thought clarity, improve mental focus, and support healthy brain functioning. 

Lion’s mane has immunomodulating properties which help maintain the immune system. Studies suggest that lion’s mane may induce nerve growth factor (NGF) synthesis in nerve cells, and can be effective in improving mild cognitive impairment.

Test marketing was conducted during Q2 and Q3 of 2021 in the U.S. market using direct ecommerce and Amazon.com, concluding with positive consumer feedback.

The five medicinal mushroom products in the Canadian line are:

  • Elevate: Blend of lion’s mane mushroom fruiting bodies, ginger root, and vitamin B3 to elevate mood and enhance cognitive clarity (tincture, 28 servings).
  • Wake: Blend of lion’s mane mushroom fruiting bodies, yerba mate, and vitamins B6 and B12 to promote wakefulness and to support cognitive performance (tincture, 28 servings).
  • Boost: Blend of shiitake fruiting bodies and turmeric to provide the body with potent antioxidants to strengthen and support immunity (tincture, 28 servings).
  • Sleep: Blend of reishi mushroom fruiting bodies, German chamomile, and melatonin to promote relaxation and sleep onset (tincture, 28 servings).
  • Think: Blend of the fruiting bodies of lion’s mane mushroom, reishi, shiitake, and chaga, yerba mate, rhodiola, choline, organic cocoa powder, and monk fruit extract. The super-shroom cognitive complex is formulated to give the brain the building blocks it needs to optimize cognitive function and to improve focus and alertness (cognitive complex powder, 30 servings).

Doseology is preparing a national marketing campaign to introduce the product line to Canadians and increase sales for distribution partners. The campaign will include a “back to nature” themed video to raise awareness of the healing role medicinal mushrooms have played for centuries, and to highlight Doseology’s commitment to providing quality, research-based products. Watch a preview of the 90-second Back to Nature campaign video.

About Product Quality
“This launch is the culmination of extensive product development, market testing, and months of planning,” said Doseology CEO Maryam Marissen.

“We’re proud to finally deliver the benefits of nootropic medicinal mushrooms to our home market. We believe our strong brand, proprietary formulations, GMP standardization, and easy-to-use products will make our medicinal mushrooms the go-to brand in Canada.”

All of the product formulations have received Health Canada Natural Product Numbers (“NPNs”). NPNs are granted to products with proven safety and effectiveness, and which are manufactured in Health Canada licensed facilities meeting good manufacturing practice (GMP) requirements.

The product line is proudly formulated using globally sourced natural ingredients and produced in Canada with industry-leading partners. Production quality and consistency are assured by processing in a modern facility with an excellent 30-year production record.

Products are vegan-friendly, cruelty-free, gluten-free, and contain no added sugar. Each formulation is third-party purity tested and verified with Certificates of Analysis (CoA) to meet Doseology’s high quality standards. 

About Adaptogenic Nutraceuticals
Adaptogens are used in herbal medicine to help people cope with physiological stress and return to homeostasis (biological balance). Significant research has shown positive effects of adaptogens with respect to stress reduction, resistance to mental fatigue, and improved attention capacity. 

The Doseology line combines adaptogens such as ginger, turmeric, yerba mate, and several mushroom species, with proven functional mushrooms such as lion’s mane, reishi, shiitake, maitake, royal sun, turkey tail, and others. These blended formulations deliver enhanced health and wellness benefits over single-ingredient products, and have a higher market value because of increased user benefits and development challenges. 

The Wake, Elevate, and Think products also include mushrooms with nootropic properties. Nootropics are supplements that improve cognitive function, such as attention, memory, creativity, or motivation. 

About the Demand and Market Opportunity
The Doseology line is positioned as a high-quality supplement for the growing number of consumers who are concerned about maintaining mental and physical health, or seeking to elevate their cognitive function through biohacking.

Consumer interest in medicinal mushrooms for health benefits is rising, with the global market valued at US$3.56 billion in 2020 and predicted to grow with a CAGR of 7.23% to 2027 (HNY Research). Canadian interest in mushroom products is growing steadily, with a 250 percent increase in search interest for lion’s mane mushroom over the past five years (Google Trends).

The larger nootropics market continues to see strong growth, and is estimated to reach US$6.69 billion by the year 2028, at a CAGR of 12.7% (Marketysers Global Consulting). 

About Purchasing and Partnering
Learn more about the benefits of Doseology’s medicinal mushroom products at doseology.com. Distributor inquiries are welcomed at hello@doseology.com.
On Behalf of the Board of Directors

Maryam Marissen
Chief Executive Officer
Doseology Sciences Inc.
maryam@doseology.com

About Doseology Sciences Inc.
Doseology Sciences Inc. (CSE: MOOD) is a British Columbia-based diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on psychedelic and non-psychedelic compounds, Doseology will offer cutting edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health.

For further information contact:

Investor Relations: investor@doseology.com
Media Inquiries: media@doseology.com
Telephone: 236-349-0064
Website: www.doseology.com

Forward Looking Statements
This corporate update contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

Industry Data
This press release includes market, industry and economic data which was obtained from various publicly available sources and other sources believed by the Company to be true. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third party sources referred to in this press release, or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying economic and other assumptions relied upon by such sources. The Company believes that its market, industry and economic data is accurate and that its estimates and assumptions are reasonable, but there can be no assurance as to the accuracy or completeness thereof. The accuracy and completeness of the market, industry and economic data used throughout this press release are not guaranteed and the Company does not make any representation as to the accuracy or completeness of such information.The CSE does not accept responsibility for the adequacy or accuracy of this release.

Posted on

Optimi Health Launches E-commerce Platform Featuring All-natural Functional Mushroom Supplements

Optimi Health Launches E-commerce Platform Featuring All-natural Functional Mushroom Supplements

B.C. company brings highest quality fruiting body mushroom formulations to the Canadian nutraceutical market 

VANCOUVER, BC (February 22, 2022) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce the official launch of its line of functional mushroom supplements to Canadian consumers. The B.C.-based company is transforming the health and wellness space with formulations made with the highest quality fruiting body mushrooms for whole body and mind optimization.

Through www.optimilife.com, Optimi is now selling high-demand functional mushroom varieties such as Lion’s Mane, http://www.optimelife.com/Reishi, Turkey Tail, Chaga and Cordyceps, which are all known for their significant health benefits and are now being widely adopted by the Western market. Through an eight-hour, eight-step hot water process using highly filtered and naturally mineralized water to break down antinutrients and optimize the fruiting body material, Optimi’s nutraceuticals deliver the maximum benefits from each ingredient.

“As a Canadian company, we are thrilled to bring the significant health benefits of functional mushrooms directly to Canadians and beyond,” says JJ Wilson, Optimi’s Board Chair. “We pride ourselves in offering an industry leading line of supplements made with the highest quality fruiting body mushrooms so Canadians can enjoy all the cognitive and physical benefits of this next level superfood. With operations set to launch at our Princeton facility, we look forward to ultimately growing and cultivating as many of our own functional mushroom strains as possible to vertically-integrate the Company, right here in Canada.”

With an evolving line of six mushroom-based supplements and a vegan protein powder featuring an advanced mushroom complex, Optimi is bringing these health benefits directly to Canadian consumers. Every Optimi product contains nutrient-dense fungi extracted from the whole fruiting body, which provides body and mind benefits such as stress resistance, immune support, energy, stamina, cognition and focus for enhanced physical and mental well-being. Optimi’s science-backed supplements are clean, powerful, and effective for maximum health optimization and increased performance.

Optimi prides itself on supplying the best mushrooms, adhering to cultivation and extraction methods that preserve the integrity and benefits of the raw material. By using clear, simple and easy-to-understand packaging, the brand aims to demystify functional mushrooms and strip away complexity for consumers.

“Our team of researchers, formulators and quality assurance experts at Optimi is second-to-none in the nutraceutical industry,” explains Bill Ciprick, CEO of Optimi Health Corp. “When we couple this expertise with the astute guidance of the Optimi Advisory Board, we can be confident in our ability to be leaders in the therapeutic and functional mushroom market.”

Optimi’s products are now available to Canadian consumers directly at www.optimilife.com and will launch in-store at select retailers later this year.

Bill Ciprick
Chief Executive Officer
Optimi Health Corp.

ABOUT OPTIMI (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN)

Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional and psychedelic mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also been granted a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION SEE CONTACT:

Media Contact
Jessica Gauci
Account Manager, Citizen Relations (on behalf of Optimi)
Email: jessica.gauci@citizenrelations.com
Phone: +1 (416) 801-7735

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/

FORWARD‐LOOKING STATEMENTS

This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

The CSE does not accept responsibility for the adequacy or accuracy of this release.Search

CATEGORIES

OPTIMI HEALTH LAUNCHES E-COMMERCE PLATFORM FEATURING ALL-NATURAL FUNCTIONAL MUSHROOM SUPPLEMENTS

22 FEBRUARY 2022

OPTIMI HEALTH APPROVED TO SUPPLY PSILOCYBIN UNDER HEALTH CANADA’S SPECIAL ACCESS PROGRAM

16 FEBRUARY 2022

OPTIMI HEALTH DEALER’S LICENSE GRANTED BY HEALTH CANADA

7 FEBRUARY 2022

OPTIMI HEALTH SUBMITS NATURAL PSILOCYBIN COMBINED DRUG DELIVERY AND EXTRACTION FORMULATIONS FOR PROVISIONAL PATENT

18 JANUARY 2022

OPTIMI HEALTH PROVIDES DEALER LICENSE UPDATE AND COMMENTS ON HEALTH CANADA’S AMENDMENTS TO THE SPECIAL ACCESS PROGRAM (SAP)

5 JANUARY 2022

OPTIMI HEALTH RECEIVES DEALERS LICENSE INSPECTION AND INTRODUCES QUALITY ASSURANCE DEPARTMENT

21 DECEMBER 2021Email

Posted on

Acquisition of Sierra Sage Herbs LLC progressing well with multiple new product launches with US retailers pending

Acquisition of Sierra Sage Herbs LLC progressing well with multiple new product launches with US retailers pending

Highlights:

  • Work continues with Sierra Sage Herbs LLC (“SSH”) management to progress the acquisition and the Company’s maiden entry into the US
  • Completion will provide Creso Pharma with an immediate US footprint and opportunities for both parties to scale the product suite, grow sales and leverage existing sales channels
  • Several product development initiatives pending – new products leverage in-house expertise of both parties
  • Initial product launch planned for a new line of Green Goo Immunity Deodorant in February 2022 – product pre-approved for sale with CVS, AmazonUS and others
  • New product ingredients include functional mushrooms and other herbal formulations
  • Functional mushrooms are a sector earmarked for entry – anticipated to be worth US$19Bn by 2030i
  • Additional product launches and distribution expansion scheduled for Q1 CY2022 – sales expected to grow Creso Pharma’s revenue profile significantly
  • SSH’s supply chain, distribution, marketing, and branding expertise to drive immediate increase in sales
  • Acquisition is the first of several opportunities for Creso Pharma to increase its exposure in the US – strong foundation to accelerate the growth of sports CBD brand ImpACTIVE

Creso Pharma Limited (ASX:CPH, OTC:COPHF, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to provide the following update on proposed acquisition target, Sierra Sage Herbs LLC (refer ASX announcement: 3 February 2022) and planned growth initiatives over the coming months.

Based in Denver, Colorado SSH is leading consumer packed goods company with a focus on plantbased and CBD products. SSH provides pioneering products under their Green Goo, Southern Butter and goodgoo brands. The Green Goo and Southern Butter ranges are currently sold across 90,000 distribution points in the US including CVS, Walgreens Walmart, AmazonUS and Target.com, with a further 20,000 points of distribution expected during Q1 CY2022. The acquisition of SSH will mark Creso Pharma’s maiden entry into the US providing the Company access to world’s largest and fastest growing CBD market, which is expected to reach US$12Bn by 2026ii.

Creso Pharma and SSH management continue to work collaboratively to complete the acquisition, which is expected to close in late March or early April 2022. Further, both parties have advanced a number of product development initiatives. Since announcement of the proposed transaction, the Creso Pharma and SSH senior management teams have held numerous extensive meetings to outline plans for accelerating market penetration of both companies’ respective product ranges.

SSH anticipates the launch of a new line of herbal ‘immunity’ deodorants which boast ingredients including functional mushrooms and other herbal formulations in February 2022. The functional mushrooms sector was of initial interest, developing products that exploit certain mushroom varieties which can deliver unique health benefits. The line is being launched under the Green Goo brand and will initially be sold through retailers including CVS, Army & Air Force Exchange Service (AAFES), AmazonUS and Natural Grocers Vitamin Cottage amongst others.

Additional products have been earmarked for development in the Q1 CY2022 include the introduction of a Valentine’s Day massage oil and pillow spray launched by Southern Butter. Green Goo is also expecting the expansion of its distribution network for several different product ranges for pain relief, skincare, and oral care.

Creso Pharma is confident that product development initiatives coupled with SSH’s established retail partner network will result in an immediate increase in sales. The acquisition establishes a footprint for the Company in the USA and provides a strong foundation to accelerate the growth of its sports CBD brand ImpACTIVE.

CEO and Managing Director, Mr William Lay said: “In a short amount of time, the strong synergistic benefits resulting from the proposed acquisition are being witnessed with the launch of the new Green Goo immunity deodorant. Both management teams have been working collaboratively to progress the acquisition as well as actively strategizing ways to increase market penetration of both the Creso Pharma and Green Goo product ranges into new markets.

“SSH has a well-established vast network of key retailers which we plan to leverage for these new products as well as introducing Creso Pharma’s product suite of innovative CBD products. We expect to see an immediate increase in our sales as we benefit from SSH’s existing revenue streams, and synergies between the two companies. I look forward to updating shareholders on the continuing work with SSH as we move to finalising the acquisition at the upcoming shareholder meeting.”

-Ends

Authority and Contact Details

This announcement has been authorised for release by the Board of Directors of Creso Pharma Limited.

For further information, please contact:

Investor Enquiries

Creso Pharma Limited

E: info@cresopharma.com

P: +61 (0) 497 571 532

About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals.

It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

Creso Pharma offices:

Australia
Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Switzerland
Allmendstrasse 11, 6310 Steinhausen, Schweiz

Canada
59 Payzant Drive, Windsor, Nova Scotia, B0N 2TO and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2TO

Forward Looking statements
This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance, and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ
materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.

i https://www.globenewswire.com/news-release/2021/11/15/2334409/0/en/Global-functional-mushroom-market-to-reach-19-33-billion-by-2030-Allied-Market-Research.html

ii https://content.brightfieldgroup.com/2021-us-cbd-market-report

Posted on

Medspresso Launches CBD and Functional Mushroom Single Serve Sachets

Medspresso Launches CBD and Functional Mushroom Single Serve Sachets

CAPE TOWN, SA / ACCESSWIRE / February 1, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:

Medspresso™ is pleased to announce the launch of its single-serve Super Booster Functional Mushroom Sachets and Active CBD Sachets.

Medspresso™ has sourced the highest quality raw materials and ingredients for the new lines. The products are ethically sourced, compliant to the highest food standards, and contain zero harmful additives, preservatives or psycho-active THC compounds. The amount of CBD in each product adheres to the legal limit allowed by South African law which amounts to 20 mg per person per day.

Both the CBD and Mushroom products are fully water-soluble and can be added to any hot or cold beverage in a convenient manner, or in the case of the mushroom sachet, enjoyed as a standalone tea. The new products fulfill the ever-growing demand for convenience which has become highly valued by CBD and mushroom health supplement consumers. The products are packaged in easy-to-open, one and two-gram sachets which can be stored and transported with ease.

“We are constantly looking at new and healthy ways to diversify Medspresso™’s portfolio and innovative product offerings for our customers. The introduction of the sachets allow customers a means to enjoy the incredible health benifits of CBD and functional mushrooms with such ease.” – says Michael Sachar, CEO of M2Bio Sciences Food and Beverage.

The sachets will be sold in retail-ready cartons of twenty sachets per unit. The consumer will have the choice to purchase their monthly supply immediately or buy it from select retailers and resellers in a single sachet format at the point of sale. The flexible nature of the product also sets the stage for various exciting co-branding opportunities with partnered beverage manufacturers, healthcare institutions, retailers as well as hospitality and tourism sectors.

“The new line of CBD and mushroom sachets is a step in the right direction when it comes to offering health and wellness to our ever growing customer base. We believe that the convenience of the single-serve sachets will allow new customers to try and love the product before they invest in larger quantities. The product will be available from our select resellers, online retailers as well as on the Medspresso website.” – says Jeff Robinson, CEO of M2Bio Sciences.

Mushroom Super Booster Sachets – Each sachet contains a mix of 100% natural Lion’s Mane, Turkey Tail, Cordyceps, and Reishi mushroom extract. Mushroom extracts have a much higher concentration of active compounds than the raw mushroom powder used in similar product offerings in the category. The extracts are created through a double extraction process, harnessing remarkably more bioavailability per dose, and in turn, the consumer is rewarded with a superior tasting product that is rapidly absorbed by the digestive system.

Active CBD Sachets – Each Active CBD sachet contains 20 mg of pharmaceutical grade CBD isolate, which is double the amount of similar CBD sachet offerings currently in the South African market. Medspresso prides itself on the quality and traceability of CBD used in all of its products for local and international CBD consumers. Only the purest CBD imported from Colorado, USA with legitimate certificates and licenses are used. The nano-emulsion formula used in the CBD isolate makes the CBD 100% water-soluble and easily absorbed through the gut, allowing the user to experience the full health benefits almost instantaneously. The powder itself is tasteless, odorless, and clear when mixed into the beverage, making for the perfect healthy addition without compromising the taste, color, and experience of the original beverage.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink:WUHN)
Website: www.m2bio.co
E-mail: info@m2bio.co

Follow us on Twitter: https://twitter.com/Medspresso
Follow us on Facebook: https://www.facebook.com/Medspresso
Follow us on YouTube: https://www.youtube.com/channel/Medspresso
Follow us on Instagram: https://www.instagram.com/medspresso.official

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/686573/Medspresso-Launches-CBD-and-Functional-Mushroom-Single-Serve-Sachets

Posted on

Doseology Completes Development and Test Marketing of Adaptogenic Mushroom Product Line

Doseology Completes Development and Test Marketing of Adaptogenic Mushroom Product Line

Vernon, British Columbia, January 6, 2022 – Doseology Sciences Inc. (CSE: MOOD) (“Doseology” or the “Company”), a British Columbia-based diversified life sciences company developing mushroom-based health and wellness solutions, announces the successful soft launch of seven new adaptogenic mushroom products in the United States, and the upcoming launch of the product line in the Canadian market during the first quarter of 2022.

Doseology’s new medicinal mushroom products have successfully completed test marketing with overwhelmingly positive ratings and reviews. Being among the most comprehensive available on the market, they will help fill the growing demand for high-quality adaptogenic nutraceuticals. The new line employs adaptogenic blends to improve on the single-extract tinctures commonly available. Blends have a higher market value because of increased user benefits and development challenges. 

The proprietary formulations make extensive use of natural mushroom fruiting bodies, pairing adaptogenic botanicals with vitamins for increased efficacy.  Significant research has shown positive effects of adaptogens with respect to stress reduction, resistance to mental fatigue, and improved attention capacity. The Doseology line combines adaptogens such as ginger, turmeric, yerba mate, and several mushroom species, with proven functional mushrooms such as lion’s mane, reishi, shiitake, maitake, royal sun, turkey tail, and others. These blended formulations deliver enhanced health and wellness benefits over single-ingredient products.

The new product line addresses the functional mushroom market, projected to grow to US$572 billion globally by 2028 with a CAGR of 6.1 percent (Data Bridge Market Research). Products in the new Doseology line address different segments of the market, including mood and depression, attention and focus, sleep and recovery, and anxiety.

In preparation for the Canadian launch, Doseology has received six Natural Product Number (NPN) licenses from Health Canada. The Company is currently exploring Canadian distribution channels, which is planned to include Amazon.ca. With US$7.14 billion in net sales (Statista, 2020), Amazon.ca is by a wide margin Canada’s largest online retailer. The Company’s direct marketing focus will enable it to quickly reach consumers who can benefit most, provide an engaging customer experience, and establish long-term relationships to maximize revenue. 

Daniel Vice, Doseology CEO and Director, comments, “After many months of product development, testing, and regulatory approval, we are pleased to finally launch our products in the U.S. market, and soon in Canada. By incorporating the nutrient-dense fruiting bodies of functional mushrooms and natural health-promoting adaptogens, our products were designed to optimize the user experience which reflects our commitment to deliver high-quality, natural solutions to improve physical & mental health.”

A core element of the Company’s mission is developing and providing psychedelic treatments for restoring mental health. Once the regulatory framework has been established, Doseology’s product line will form the foundation for psilocybin-based therapeutics, creating an entirely new market and fulfilling the Company’s vision of better mental health and wellness for millions globally.

Doseology has completed its application with Health Canada to become a “Licensed Dealer” under the Controlled Drugs and Substances Act (Canada), which would permit the production of psychedelic compounds including psilocybin and psilocin, and mark a significant milestone in achieving the Company’s vision.

These announced developments will give consumers better access to the healing power of medicinal mushrooms, and bring Doseology closer to delivering innovative wellness solutions and mental health therapies.

Learn more about Doseology’s medicinal mushroom product line at doseology.com.

On Behalf of the Board of Directors

Daniel Vice
Chief Executive Officer and Director
Doseology Sciences Inc.

About Doseology Sciences Inc.
Doseology Sciences Inc. (CSE: MOOD) is a British Columbia-based diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on psychedelic and non-psychedelic compounds, Doseology will offer cutting-edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health.

For further information contact:
Investor Relations: investor@doseology.com
Media Inquiries: media@doseology.com
Telephone: 236-349-0064
Website: www.doseology.com

Forward Looking Statements
This corporate update contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Posted on

Better Plant Adds Neonmind Superfood Mushroom Coffees in the United States on Faire Wholesale Marketplace

Better Plant Adds Neonmind Superfood Mushroom Coffees in the United States on Faire Wholesale Marketplace

Vancouver, B.C. – December 10, 2021: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FRA: YG3) (“Better Plant”) a wellness company that develops and sells plant-based products, is pleased to announce that it’s full line of NeonMind Superfood Mushroom Coffees are now available for purchase by retailers  in the United States (“U.S.”) on Faire Wholesale Marketplace, an online wholesale marketplace.

Faire currently serves over 170,000 independent retailers across North America, representing more retail locations than Marks & Spencer, Boots, Aldi, Starbucks, and Tesco combined.

“Being on Faire will showcase our coffee products  to retailers that are outside of our typical demographic”, says Amber Allen, Director of Sales for Better Plant. “We look forward to promoting NeonMind products on this platform and connecting with many diverse buyers.”

Faire provides a holistic, end-to-end platform that enables independent retailers to build, grow, and run their businesses. Leveraging the Faire platform benefits retailers with perks such as payment flexibility and security, free returns, shipping solutions and data-driven recommendations.

Better Plant owns four NeonMind mushroom coffee blends which are sold in the U.S.: two roasted blends and two instant coffee blends. From improving memory, alertness, and cognitive function to supporting the immune system, eliminating toxins and fighting mental and physical stress, NeonMind’s mushroom coffees put health and wellness at the forefront.

According to a report by MarketsandResearch.com, the global superfoods market size is expected to reach USD 272.47 billion by 2028. Mushrooms that are featured in NeonMind coffees, such as reishi and turkey tail are considered to be popular superfoods due to their healthful properties.

About Faire:

Faire is a curated wholesale marketplace connecting more than 170,000 North American retailers with thousands of emerging and established brands. Faire enables independent retailers to grow their business with the advantages of big box terms and empowers makers to seamlessly build and run their wholesale business. Faire was founded in 2017 and is powered by the idea that the future is local. Faire is backed by investors including Y Combinator, Lightspeed Venture Partners, Forerunner Ventures, Khosla Ventures, Sequoia Capital, Founders Fund, and DST Global. The company is headquartered in San Francisco, Kitchener-Waterloo, and Salt Lake City. To learn more, visit www.Faire.com.

Other News

On November 30, 2021 Better Plant completed the sale of its previously wholly-owned subsidiary, Wright & Well Inc., which held the licensing rights to a cannabis topicals brand in Oregon, U.S., to a non related party for an all cash deal of twenty thousand dollars.

On November 29, 2021 Better Plant changed the nature of its broker representation agreement with Hive Naturals (formerly known as Thank You Merci) that was announced on February 4, 2021. Hive Naturals was engaged to represent Better Plant’s wholly-owned subsidiaries Jusu Wellness and Jusu Bar in Canada and the U.S.. Going forward, Hive Naturals will concentrate its efforts solely on the existing Jusu Wellness accounts with Whole Foods Market and Healthy Planet, Canada.

“Our new relationship with Hive Naturals will allow us to continue to ensure exceptional customer service and to help organically grow sales within these key accounts”, says Amber Allen, Director of Sales for Better Plant.

Better Plant continues to engage Nationwide Natural Foods Inc. as a distributor for Jusu Bar in Canada, and is expanding distribution points for Jusu Bar and Jusu Wellness products through its own in-house sales team.

About Better Plant Sciences Inc.

Better Plant has a catalog of hundreds of product formulas and develops, commercializes, markets and sells over 50 products through the brands Jusu, NeonMind and Urban Juve. Better Plant products are sold through a network of over 150 online and brick-and-mortar retail locations including Whole Foods Market, Pharmasave, Healthy Planet and Vitasave. Better Plant has a talented team with expertise in digital design, branding, eCommerce and digital marketing and offers operational, financial, and other services to companies with emerging and fast growing businesses.

For more information on Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.

Penny White, President & CEO

penny@betterplantsciences.com

1-833-515-2677

Investor Relations:

Alexandra Dumanski

invest@betterplantsciences.com

1-833-515-2677

Sales Inquiries:

Amber Allen, Director of Sales

amber@betterplantsciences.com

604-808-8118

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen. Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

Psyence Group Functional Mushroom Brand “GOODMIND” Commences National Roll-Out In South Africa’s Largest Coffee Retail Chain

Psyence Group Functional Mushroom Brand “GOODMINDTM” Commences National Roll-Out In South Africa’s Largest Coffee Retail Chain

Toronto, Canada/ December 2, 2021 / Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce that its joint venture functional mushroom brand GOODMINDTM has partnered with one of Africa’s largest coffee retail chains, “vida e caffè”, to commence the rollout of its GOODMINDTM functional mushroom brand in select vida e caffè’s coffee shops in South Africa.

The product is available for sale in a sachet format, which can be added to any beverage, or it can be ordered as a GOODMINDTM Functional Mushroom Cappuccino. GOODMINDTM is jointly owned by Psyence and South African natural wellness company Goodleaf.

“Following the launch of our first Functional Mushroom product, GOODMINDTM (in capsule format) in August 2021, we recognised the opportunity to extend the GOODMINDTM offering. We have now developed GOODMINDTM water-soluble, mushroom powder sachets, which blends perfectly with coffee and other beverages,” says Jody Aufrichtig, Executive Chairman Psyence Group.” We are proud of the GOODMINDTM products we have developed and that we are able to generate revenue from having our wellness products on shelves.”

Goodmind Vida E Caffe

Goodleaf CEO and Founder Warren Schewitz says: “Collaborating with vida e caffè to launch South Africa’s first Functional Mushroom Cappuccino made perfect sense. vida e caffè has a network of over 250 coffee stores nationwide and the Functional Mushroom Cappuccino will be available in a selection of these stores. The brand is synonymous with innovation and is experienced in bringing new products to market.”

Darren Levy CEO, vida e caffè says:  “We are constantly on a journey to see how we can enhance our coffee and health offering to the end consumer, and are committed to staying on trend with global coffee developments. Following previous collaborations in the CBD space and recent collagen additions to our menu, we have seen that our consumers enjoy having functional benefits added to their daily brew. We are excited to be collaborating with the GOODMIND team on this new and innovative coffee add-on offering, promoting a healthy body and mind.”

The global Functional Mushroom market was valued at USD 25.4 billion in 2020, and is projected to reach a CAGR of 8.44% during the forecast period 2021-2026. This is according to a Functional Mushrooms Market 2021 report published by Research and Markets in October 2021. The report highlights that while demand for mushroom-based products had been increasing for some time, functional mushrooms have been ‘brought into the spotlight’ as a result of Covid-19 and the category is experiencing accelerated growth.

The GOODMIND™ Functional Mushroom range has been developed using a blend of adaptogenic, non-psychedelic super mushrooms. The GOODMIND™ mushroom powder sachets are a blend of eight functional mushrooms, predominantly Lion’s Mane, Shiitake, Cordyceps and Chaga.

ABOUT PSYENCE GROUP: www.psyence.com

Psyence is a public life science biotechnology company listed on the Canadian Securities Exchange and (CSE: PSYG) and quoted on the OTCQB (OTCQB: PSYGF), with a focus on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.

Our name “Psyence” combines the words psychedelic and science to affirm our commitment to producing psychedelic medicines developed through evidence-based research.

Informed by nature and guided by science, we built and operate one of the world’s first federally licensed commercial psilocybin mushroom cultivation and production facilities in Lesotho, Southern Africa.

Our team brings international experience in both business and science and includes experts in mycology, neurology, palliative care, and drug development.  We work to develop advanced natural psilocybin products for clinical research and development.  We have entered into a long term joint venture to launch mushroom-based mental wellness focused nutraceutical products, the GOODMIND™ collection, to support improved focus, calm, and sleep.

Our key divisions, Psyence Production, Psyence Therapeutics, and Psyence Function, anchor an international collaboration, with operations in Canada, the United Kingdom, Jamaica, South Africa and a presence in the United States and Australia.

For more info on the GOODMIND™ website: https://foragoodmind.com/

About vida e caffè

 vida e caffè is a privately-owned coffee shop franchise and supplier of beverage products in South Africa. The name vida e caffè mixes Spanish or Portuguese for ‘life’ with Italian for ‘and coffee’. The coffee chain has over 250 stores throughout South Africa and 22 on the rest of the African continent.

Certain statements in this news release related to Psyence Group Inc and its subsidiaries (collectively “the Company“) are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding consumer uptake of GOODMINDTM products and functional mushroom products in general in South Africa, product requirements, consumer demands and product market fit in South Africa, revenue generation from the GOODMINDTM products, the size and growth of the global Functional Mushroom market, the effect of the COVID-19 epidemic, and market conditions and economic factors effecting the GOODMINDTM business and roll-out and the functional mushroom market in general. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

Posted on

GIVEAWAY ALERT 🚨

Join the CPA Community & Win!

You could win $4,000+ in prizes for supporting legal access to psychedelics!

By becoming a member of the Canadian Psychedelic Association, you can help bring new regulations forward so Canadians in need can receive lifesaving psilocybin treatments.

If that’s not enough, you’ll also be entered to win an incredible prize package including:

  • A scholarship towards a Holos Plant Medicine retreat (Value: $1,500)
  • A 2-night stay at the Sentinel Retreat Centre (Value: $500)
  • A functional mushroom wellness package from Eversio Wellness (Value: $300)
  • 1 of 3 Physiology of Trauma premium masterclass packages from Nectara (Value: $900)
  • And more!

Plus, your membership unlocks tons of other benefits such as conference discounts, exclusive interviews, resources, and media content.

Purchase a membership before December 10th to be entered in the giveaway!